Premium
A monoclonal antibody recognizing plasminogen and plasmin—altered reactivity in psoriatic lesions
Author(s) -
JUSTUS C.,
MÜLLER S.,
KRAMER M. D.
Publication year - 1987
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1987.tb07347.x
Subject(s) - plasmin , monoclonal antibody , plasminogen activator , antibody , immunofluorescence , microbiology and biotechnology , pathology , pathogenesis , monoclonal , psoriasis , biology , epidermis (zoology) , immunology , medicine , enzyme , endocrinology , biochemistry , anatomy
summary To study the organization of the plasminogen activator/plasminogen‐plasmin (PA/PG‐P) system in human epidermis we raised monoclonal antibodies with specificity for human plasminogen and plasmin (PG‐P), Monoclonal antibody P2, which appeared most suitable for immunohistology, is a mouse monoclonal antibody of IgG 1 subtype, specific for the precursor enzyme plasminogen and for the high molecular weight chain of the active enzyme, plasmin. Immunofluorescence analysis of normal human epidermis revealed that reactivity with P 2 was confined to the basal cell layer. In psoriatic lesions, however, this regional organization was not found. Immunoreactivity in this case was scattered throughout all the hyperproliferating cell layers, which is taken as evidence for an altered distribution of PG‐P in psoriatic lesions. In psoriasis other components of the PA/PG‐P system have previously been found to be altered. In this context our findings add to the hypothesis that this system may be involved in the pathology or the pathogenesis of psoriatic lesions.